What is Evommune 's gain (loss) on sale of derivatives?

Evommune (EVMN) reported gain (loss) on sale of derivatives of $206.46K in Q1 2026.

How has Evommune 's gain (loss) on sale of derivatives changed year-over-year?

Evommune 's gain (loss) on sale of derivatives increased by 111.2% year-over-year, from -$1.84M to $206.46K.

What does gain (loss) on sale of derivatives mean?

The net financial impact resulting from the disposal or settlement of derivative instruments. It captures the realized performance of hedging or speculative financial positions held by the company.

Evommune EVMN Gain (loss) on sale of derivatives

Gain (loss) on sale of derivatives at other companies

National Health InvestorsNHI

$0-100%

NB Bancorp, Inc.NBBK

$201K+128%

DJT

Trump Media & Technology GroupDJT

$16.52M+1,689%

Diversified Energy DEC

-$150.48M-188%

Allegro MicroSystems, Inc.ALGM

$0—

Construction PartnersROAD

$1.38M-26.0%

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfDerivatives.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's gain (loss) on sale of derivatives.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's gain (loss) on sale of derivatives?: Evommune (EVMN) reported gain (loss) on sale of derivatives of $206.46K in Q1 2026.
How has Evommune 's gain (loss) on sale of derivatives changed year-over-year?: Evommune 's gain (loss) on sale of derivatives increased by 111.2% year-over-year, from -$1.84M to $206.46K.
What does gain (loss) on sale of derivatives mean?: The net financial impact resulting from the disposal or settlement of derivative instruments. It captures the realized performance of hedging or speculative financial positions held by the company.